New England Journal of Medicine· 2015Q1

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu et al.

2,858citations
Q1SCImago
2015year

Short summary

Adding docetaxel to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer significantly increased overall survival by a median of 13.6 months (57.6 vs. 44.0 months).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pulmonary and Respiratory Medicine

Pulmonary and Respiratory MedicineMedicine